Replies to post #258739 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

"Novartis still hasn't solved its CAR-T manufacturing issues."

https://www.biopharmadive.com/news/novartis-kymriah-car-t-manufacturing-difficulties-cell-viability/568830/

[Evaluate]

you wrote:

IIRC, they did a slide presentation at Phacilitate in Jan '19, which went into a degree of detail about the manufacturing process, and stated something about further manufacturing refinement meant that only 1 gram (I think) of tumor material was now needed for batch production, and they mentioned (I think) potential production capacity for Sawston (or might have been Memphis) in the tens of thousands. Which of course could not be the case, if what you asserted was accurate.

So I'll do the same as you and assert you must be wrong, then humbly withdraw my remarks if you are proved correct.

Unfortunately that slide deck, which was available on the NWBO website, appears to no longer be there.
Don't know if anybody retained it or can find it.

I did keep slidedeck = 26 pages = NW-Bio-Phacilitate-Presentation2009-01.pdf

I do not see the specific details you reference above.

I do see, on page 26:
DCVax®-L: Operationally Practical for Commercialization
• Only 1 manufacturing run per patient
• Frozen product (“off the shelf” doses); frozen shelf life validated
• Amenable to automation
• Simple administration to patient: intra-dermal injection
• Compatible with Standard of Care and diverse experimental treatments
• Excellent safety profile – no inpatient or ICU stays and no added drugs to manage side effects